Synthesis, Characterization, and Preclinical Evaluation of New Thiazolidin-4-ones Substituted with p-Chlorophenoxy Acetic Acid and Clofibric Acid against Insulin Resistance and Metabolic Disorder
Table 3
Effect of thiazolidin-4-ones on in vitro glucose uptake in absence and presence of insulin.
S. no.
Groups
Glucose uptake (mg/g/45 min)
In absence of insulin
In presence of insulin
Mean ± S.E.M. ()
Mean ± S.E.M. ()
1
Glucose control
8.09 ± 0.51
12.11 ± 1.34
2
Compound 2a
1.89 ± 1.45
10.33 ± 1.21
3
Compound 2b
6.19 ± 0.31
7.36 ± 0.25
4
Compound 2c
10.12 ± 0.52
14.88 ± 0.86
5
Compound 2d
9.84 ± 0.61
8.16 ± 0.11
6
Compound 2e
19.00 ± 1.27a
23.42 ± 0.32b
7
Compound 2f
6.03 ± 0.33
8.33 ± 0.15
8
Compound 2g
6.45 ± 0.13
7.08 ± 0.19
9
Compound 2h
7.61 ± 0.18
7.28 ± 0.38
10
Compound 2i
5.55 ± 0.14
6.44 ± 1.19
11
Compound 2j
9.54 ± 0.21
3.68 ± 1.79
12
Compound 2k
5.82 ± 0.18
7.21 ± 0.15
13
Compound 2l
6.43 ± 0.10
9.99 ± 0.10
14
Compound 2m
8.12 ± 0.82
12.87 ± 0.15
15
Compound 3a
20.44 ± 0.17a
25.01 ± 0.29b
16
Compound 3b
7.77 ± 0.29
11.51 ± 0.02
17
Compound 3c
12.24 ± 0.10
10.50 ± 0.81
18
Compound 4a
7.53 ± 1.10
7.98 ± 0.83
19
Compound 4b
6.10 ± 0.83
7.72 ± 0.21
20
Compound 4c
0.97 ± 0.59
4.82 ± 0.55
21
Compound 4d
3.77 ± 0.47
5.54 ± 0.49
22
Pioglitazone
13.37 ± 0.26a
25.23 ± 0.34b
a and b represent as compared to glucose control in absence/presence of insulin, respectively.